financetom
Business
financetom
/
Business
/
US Antimony Stock Surges On $245 Million Defense Stockpile Contract
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US Antimony Stock Surges On $245 Million Defense Stockpile Contract
Sep 23, 2025 12:39 PM

United States Antimony Corporation ( UAMY ) shares are rising Tuesday after the company announced a collaboration with the U.S. Defense Logistics Agency (DLA).

What Happened: U.S. Antimony has been awarded an Indefinite Delivery Indefinite Quantity (IDIQ) sole-source contract by the DLA Strategic Materials for up to $245 million. The contract is for the purchase of antimony metal ingots to aid in the replenishment of the National Defense Stockpile.

The contract represents the next phase of a growing collaboration between U.S. Antimony and the Department of Defense (DOD)/DLA, which began accelerating in late 2024. Fulfillment will begin with the first delivery order, which is anticipated this week. Both of U.S. Antimony’s North American smelting facilities already have the capability to produce antimony metal ingots that meet the government’s stringent specifications.

Gary Evans, chairman and CEO of U.S. Antimony, highlighted the strategic importance of the contract, noting that it dwarfs the company’s total revenue for 2024 of $14.9 million. Evans also said U.S. Antimony is the only fully integrated antimony operation outside of China.

“It’s incredibly meaningful for all our employees to play such a strategic role in strengthening our nation’s defense readiness and having the knowledge, expertise, and history that USAC can and will deliver under our contractual obligations,” Evans said.

USAC operates North America’s only two antimony smelters that have been processing antimony for decades. The company continues to expand its sources for procuring antimony ore feedstock from countries around the world, along with developing its own antimony-bearing mineral acreage positions in Alaska and Montana.

UAMY Price Action: U.S. Antimony shares were up 14.74% at $7.40 at the time of publication on Tuesday, according to Benzinga Pro. U.S. Antimony stock has surged over 300% year-to-date.

Read Next:

United States Antimony ( UAMY ), Better Home & Finance, PDF Solutions And Other Big Stocks Moving Higher On Tuesday

Image: Zakharchuk/Shutterstock.com

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US State Dept OKs potential sale of missiles to Denmark, Pentagon says
US State Dept OKs potential sale of missiles to Denmark, Pentagon says
Jun 7, 2024
WASHINGTON, June 7 (Reuters) - The U.S. State Department has approved the potential sale of advanced medium-range air-to-air missiles and related equipment to Denmark for an estimated cost of $215.5 million, the Pentagon said on Friday. Denmark has asked to buy 84 AIM-120C-8 Advanced Medium-Range Air-to-Air Missiles and three AIM-120 AMRAAM guidance sections, the Pentagon said. The principal contractor will...
Copper output from Chile's Codelco down 6% in April
Copper output from Chile's Codelco down 6% in April
Jun 7, 2024
SANTIAGO, June 7 (Reuters) - Copper production from Chile's state-run miner Codelco, the world's largest producer of the metal, dropped 6.1% in April compared to the same month last year to total 95,100 metric tons, data from copper commission Cochilco showed on Friday. Copper output also fell during the month at Chile's Escondida mine, though it edged up 1.9% in...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Jun 7, 2024
(Reuters) - A 15-day course of Pfizer's ( PFE ) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's...
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Jun 7, 2024
03:16 PM EDT, 06/07/2024 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis. Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved